IVVD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IVVD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.
As of today, Invivyd's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.
For the Biotechnology subindustry, Invivyd's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Invivyd's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:
* The bar in red indicates where Invivyd's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.
Invivyd (NAS:IVVD) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation
Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.
In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.
Thank you for viewing the detailed overview of Invivyd's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.
Adimab, Llc | 10 percent owner, other: See Remarks | 7 LUCENT DRIVE, LEBANON NH 03766 |
William E. Duke | officer: Chief Financial Officer | C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807 |
Sara Cotter | director | 1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103 |
Allen Robert D. Iii | officer: Chief Scientific Officer | 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451 |
Stacy Price | officer: Chief Tech. and Manuf. Officer | 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451 |
Jeremy Gowler | officer: COO & CCO | 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451 |
Rebecca Dabora | officer: Chief Tech and Manuf Officer | 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451 |
Peter Schmidt | officer: Chief Medical Officer | 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451 |
Jill Andersen | officer: Chief Legal Officer, Secretary | 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451 |
Christine Lindenboom | director | 1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451 |
Frederick W Driscoll | officer: Interim CFO | |
David Hering | director, officer: Chief Executive Officer | 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451 |
Marc Elia | director, other: See Remarks | C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472 |
M28 Capital Management Lp | other: See Remarks | 700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902 |
Clive Meanwell | director, 10 percent owner | THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
From GuruFocus
By PRNewswire PRNewswire • 03-30-2023
By Marketwired • 09-05-2023
By Marketwired • 06-26-2023
By sperokesalga sperokesalga • 03-30-2023
By sperokesalga sperokesalga • 03-30-2023
By sperokesalga sperokesalga • 05-11-2023
By Marketwired • 07-17-2023
By sperokesalga sperokesalga • 04-12-2023
By PRNewswire PRNewswire • 03-31-2023
By Marketwired • 09-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.